Myriad Genetics (MYGN) Treasury Shares (2014 - 2026)

Myriad Genetics (MYGN) has 13 years of Treasury Shares data on file, last reported at $8.9 million in Q1 2026.

• Treasury Shares for Q1 2026 came in at $8.9 million, up 74.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.9 million (up 74.51% YoY), and the FY2025 annual result was $7.1 million, up 33.96% from the prior year.
• Treasury Shares improved to $8.9 million in Q1 2026 per MYGN's latest filing, from $7.1 million in the prior quarter.
• Over five years, Treasury Shares peaked at $8.9 million in Q1 2026 and troughed at $3.7 million in Q3 2022.
• A 5-year average of $5.4 million and a median of $5.1 million in 2025 frame the typical range for Treasury Shares.
• The sharpest annual moves came in 2025 and 2026: Treasury Shares decreased 8.93% in 2025, then soared 74.51% in 2026.
• A 5-year view of Treasury Shares shows it stood at $3.7 million in 2022, then gained by 18.92% to $4.4 million in 2023, then climbed by 20.45% to $5.3 million in 2024, then surged by 33.96% to $7.1 million in 2025, then rose by 25.35% to $8.9 million in 2026.
• Business Quant data shows MYGN's Treasury Shares at $8.9 million in Q1 2026, $7.1 million in Q4 2025, and $7.5 million in Q3 2025.